Home
Contact Us
Site Map
 
 

Press Release Archive


For Immediate Release: 9/7/2004


Agilect® Reduced Tremor and Severity of "Off" Time

Positive data presented at European Federation of Neurological Societies Annual Meeting


Paris, France - September 7, 2004 — According to two separate posters presented this week, moderate to advanced Parkinson's disease (PD) patients who added AGILECT® (rasagiline mesylate) to their levodopa therapy experienced a reduction in tremor and, during "off" time, improved motor function. "Off" time refers to periods of time when Parkinson's symptoms are not adequately controlled.

"Both of these sets of data add to the body of evidence that AGILECT® will be an important new treatment option for people living with PD," said Olivier Rascol, M.D., Ph.D., professor of pharmacology, University of Toulouse School of Medicine, Toulouse, France, and lead author of the poster detailing the analysis of tremor data and a contributing author of the severity of "off" time poster. "These data demonstrated that AGILECT® improved a common symptom and motor complications of moderate to advanced PD — tremor severity and 'off' time."

Additionally, other data have demonstrated a reduction of "off" time and improved patient performance in both the "on" and "off" states in patients using AGILECT®.

The findings from these analyses of the LARGO trial data were presented this week at the European Federation of Neurological Societies (EFNS) annual meeting. LARGO stands for "Lasting effect in Adjunct therapy with Rasagiline Given Once daily." The LARGO trial, conducted in Europe, Israel and Argentina, compared the effects of once-daily AGILECT® (1 mg) or entacapone (200 mg with each dose of levodopa) or placebo added to optimized levodopa and other concomitant PD therapy in PD patients experiencing significant daily motor fluctuations. In addition to optimized levodopa therapy, approximately 60 percent of patients in this study were also taking a dopamine agonist.

A post-hoc analysis evaluated the impact of AGILECT® (rasagiline mesylate) on tremor — a common PD symptom. Overall, patients who used AGILECT® e

Printer Friendly Version

 
Go to Top